Back to News
Market Impact: 0.2
HepaRegeniX Completes Darizmetinib Treatment Phase for First Patient Undergoing Major Liver Resection in Phase 1b Liver Regeneration Study
Source: GlobeNewswire
Healthcare & Biotech
The first patient has completed a 28-day treatment course with darizmetinib, marking an early clinical-development milestone. A second Phase 1b pilot cohort is expected to enroll 10 patients and complete by Q4 2026, with efficacy and safety results still pending.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Trump admin says it will save $2.2 billion by kicking off 760,000 Affordable Care Act enrollees over fraud claims
- US and Iran Sit Down for Talks at the UN: Evening Briefing Americas
- In Senegal, a mother’s ordeal exposes a health system under strain
- Halozyme Therapeutics completes $1.5 billion convertible notes offering
- Trump administration removes around 760,000 Obamacare enrollments, alleging fraud
- Dozens of people sue GLP-1 drug companies over alleged vision loss